NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Updated: Apr 26, 2022
NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
The purpose of this study is to find the number of natural killer (NK) cells from non-HLA matched donors that can be safely infused into patients with cancer. NK cells are a form of lymphocytes that defend against cancer cells. NK cells in cancer patients do not work well to fight cancer. In this study, the NK cells are being donated by healthy individuals without cancer who are not "matched" by human leukocyte antigen (HLA) genes to patients. After receiving these NK cells, patients may also be given a drug called ALT803. ALT803 is a protein that keeps NK cells alive, helps them grow in number and supports their cancer-fighting characteristics. HLA-unmatched NK cell infusion is investigational (experimental) because the process has not approved by the Food and Drug Administration (FDA).
Sponsor:
David Wald, Case Comprehensive Cancer Center
United States, Ohio
ClinicalTrials.gov Identifier: NCT02890758
Official Title: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803
First Posted : September 7, 2016
Click here to see details on ClinicalTrials.gov
Biological: Natural Killer (NK) Cells
Biological: ALT803
Nogapendekin Alfa (Code C107503)
ALT 803
ALT-803
ALT803
Fusion Protein Consisting of IL-15N72D and IL-15RaSu/FC
IL-15N72D/IL-15Ra-Fc
IL-15N72D:IL-15RaSu/Fc Fusion Complex
N 803
N-803
N803
Nogapendekin Alfa
NOGAPENDEKIN ALFA